C3L-00965
— · cohortSQ2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ2
- subtype
- cohortSQ2
- age_years
- 63.80561259
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.570
- MYC_TARGETS_V1+0.540
- E2F_TARGETS+0.490
- G2M_CHECKPOINT+0.420
- SPERMATOGENESIS+0.250
- OXIDATIVE_PHOSPHORYLATION+0.240
- PANCREAS_BETA_CELLS+0.240
- UNFOLDED_PROTEIN_RESPONSE+0.190
- DNA_REPAIR+0.180
- UV_RESPONSE_UP+0.140
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.710
- INTERFERON_GAMMA_RESPONSE-0.560
- COMPLEMENT-0.450
- IL6_JAK_STAT3_SIGNALING-0.430
- INFLAMMATORY_RESPONSE-0.430
- COAGULATION-0.400
- TGF_BETA_SIGNALING-0.390
- ALLOGRAFT_REJECTION-0.370
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.360
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_JZRM1S3T | medulloblastoma | — | 0.948 |
| 2 | C3L-01285 | — | cohortSQ2 | 0.939 |
| 3 | BS_W644VEVE | medulloblastoma | — | 0.937 |
| 4 | SRR5088911 | — | — | 0.933 |
| 5 | BS_ZXYDSBM9 | medulloblastoma | — | 0.931 |
| 6 | BS_AM70R8RG | medulloblastoma | — | 0.928 |
| 7 | BS_9NZ2D6AD | medulloblastoma | — | 0.927 |
| 8 | BS_S69QZAJR | medulloblastoma | — | 0.926 |
| 9 | BS_YETBN0RQ | medulloblastoma | — | 0.925 |
| 10 | MBCProject_0006_T1_RNA | — | B | 0.925 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.570 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.540 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.490 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.420 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.250 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.240 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.240 | Cobimetinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.190 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.180 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.140 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.050 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.040 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.040 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.010 | Idelalisib | — uncovered |